BIONIQ: a “pay-for-performance” exit reshaping venture dynamics
📩 Pour nous contacter: redaction@decode.media
The sale of Bioniq to Herbalife is not merely a consolidation move in the dietary supplements sector. It also provides a reference point for how exit structures are evolving in a post-correction environment, where valuation is no longer asserted upfront but validated over time.
Behind a headline figure that could reach €138.5 million, the reality of the deal is more nuanced: €50.75 million is guaranteed, with up to €87.75 million tied to performance. In other words, more than 60% of the value remains to be proven after signing.
The financial structure of the transaction is all the more atypical given that, of the announced $55 million, only $10 million is paid at closing, with the remaining balance spread over five years.
A staged valuation indexed to execution
This type of structuring reflects a broader trend in M&A. Where acquirers once paid upfront for projected growth, they now favor mechanisms that align valuation with actual performance.
In Bioniq’s case, this logic is particularly visible given that the company raised approximately €27.2 million, including a €14.1 million Series B in 2024, at a valuation of around €75.7 million. The current agreement introduces a significant gap between immediately realized value and potential value.
This differential is not merely a matter of financial prudence; it also reflects a more structural question: to what extent can Bioniq’s value proposition, based on biomarker-driven personalized nutrition, scale within an industrial environment?
Earn-out as a risk allocation instrument
The earn-out, which in this case may exceed the guaranteed amount, functions as a mechanism for redistributing risk between seller and buyer. For the acquirer, it limits upfront exposure while preserving an option on future value creation. For the founder, it extends the liquidity horizon and ties a significant portion of proceeds to post-acquisition execution.
Such structures introduce a degree of ambiguity into the very notion of an exit. The transaction is no longer a clean break, but rather a transition into a new phase where value creation remains partly to be delivered.
In this context, managerial continuity, with Vadim Fedotov joining Herbalife’s leadership team, becomes central. It helps maintain alignment between the initial promise and its operational execution.
This configuration reflects a common practice in such transactions, where founders typically remain in place for two to three years to ensure integration, secure the milestones tied to the earn-out, and transfer intangible assets (product, teams, vision) into the acquiring organization.
One potentially decisive unknown remains: Bioniq’s ability to retain the active support of its high-profile business angels, notably Cristiano Ronaldo and Diogo Dalot. Their role goes beyond that of financial investors, they act as credibility vectors and drivers of adoption. The question is whether they will continue to embody the product promise within the Herbalife ecosystem.
Distribution and technology: an equation to validate
The strategic rationale of the deal therefore rests on the apparent complementarity between the two companies. Bioniq brings a data-driven technological layer, with over 6 million biomarker data points and a proprietary personalization engine. Herbalife, for its part, offers a global distribution infrastructure spanning 95 markets and relying on more than 2 million distributors.
A broader reading of the venture market
Beyond the specific case of Bioniq, the transaction reflects a broader recomposition of the market. Since the valuation reset that began in 2022, both investors and acquirers have shifted toward more gradual approaches, where value creation is sequenced and conditional.
This evolution is not solely about caution; it also reflects a deeper integration of operational constraints into valuation models. Growth projections have not disappeared, but they are now framed by mechanisms that test their robustness under real-world conditions.
In this environment, startups operating hybrid models, combining technology, data, and distribution, are particularly exposed. Their value depends less on a standalone product than on their ability to integrate into existing ecosystems.
It is precisely in this gap, between announced valuation and realized value, that an increasing share of exit economics now resides. The question remains how this value is distributed between founders and investors: earn-out structures, by tying a significant portion of the price to future performance, can introduce imbalances, particularly when founders become constrained by targets they no longer fully control within the acquiring organization.
